Taking stock of the drug industry, from the lab to the medicine chest

July 9, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Good evening. This week only, get 50% off your first year of STAT+ and enjoy unlimited access to award-winning journalism, premium data tools, discounted event tickets, and much more. Thanks for reading.

Nardus Engelbrecht/AP Gilead to provide HIV prevention drug to 2 million people in lower-income countries at cost Gilead and the Global Fund will provide 2 million doses of its groundbreaking HIV prevention drug. Notably, the deal does not include PEPFAR. By Jason Mast and Ed Silverman STAT+ | Merck to buy lung-disease biotech Verona Pharma for $10 billion The centerpiece of the acquisition is Ohtuvayre, a treatment for chronic obstructive pulmonary disease that secured U.S. approval last year. By Adam Feuerstein STAT+ | Novartis wins approval for newborn malaria treatment Today's biotech news covers Novartis winning approval for newborn malaria treatment, and Cogent's immune drug results. By Elaine Chen Matt Slocum/AP STAT+ | HHS backtracks on pledge to disclose new vaccine advisers' conflicts of interest RFK Jr., a longtime critic of health care conflicts of interest, has not disclosed financial information for his handpicked team of vaccine advisers. By Isabella Cueto Getting off antidepressants isn't as risky as is widely believed, review suggests A Kennedy claim comparing SSRIs to heroin raised questions. New review says antidepressant withdrawal symptoms are less common than believed By Theresa Gaffney

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser